O'Keeffe S, Grimes H, Finn J, McMurrough P, Daly K
Department of Cardiology, University College Hospital, Galway, Ireland.
Cardiology. 1992;80(2):100-5. doi: 10.1159/000174986.
Lymphocyte potassium and magnesium were measured before and 3 months after the introduction of captopril in 18 patients taking diuretics for congestive heart failure. Compared to 32 healthy controls, 9 patients who had been on potassium supplements plus frusemide had decreased baseline lymphocyte magnesium and potassium concentrations (p less than 0.01), in spite of similar plasma electrolyte levels. There was a significant (p less than 0.01) increase in both lymphocyte potassium and magnesium levels after 3 months' treatment with captopril and frusemide in these patients. Nine patients who had been taking a potassium-sparing combination diuretic also had an increase in lymphocyte magnesium (p less than 0.05) following the introduction of captopril. Increased intracellular potassium and magnesium may be one mechanism whereby angiotensin-converting enzyme inhibitors reduced arrhythmias and improve survival in patients with congestive heart failure.
对18例因充血性心力衰竭而服用利尿剂的患者，在引入卡托普利之前及之后3个月测定淋巴细胞钾和镁的含量。与32名健康对照者相比，9例服用钾补充剂加速尿的患者，尽管血浆电解质水平相似，但基线淋巴细胞镁和钾浓度降低（p<0.01）。这些患者在接受卡托普利和速尿治疗3个月后，淋巴细胞钾和镁水平均显著升高（p<0.01）。9例一直服用保钾联合利尿剂的患者在引入卡托普利后，淋巴细胞镁含量也有所增加（p<0.05）。细胞内钾和镁增加可能是血管紧张素转换酶抑制剂减少充血性心力衰竭患者心律失常并提高生存率的一种机制。
